On diagnosis of rejection, mice were killed and the whole eye was enucleated. The eye was embedded in optimal cutting temperature compound (OCT; Sakura Finetek Europe BV, Zoeterwoude, The Netherlands) and was frozen on a liquid nitrogen-cooled duralumin plate. Specimens were stored at −70°C. Cryostat sections 8-μm thick were cut, and indirect frozen section immunohistochemical analysis was performed using the following primary antibodies: rat anti–mouse CD4, RM4–5 (BD Biosciences, San Jose, CA) 1:100 dilution; rat anti–mouse CD8, YTS105.18 (Serotec, Raleigh, NC) 1:100 dilution; rat anti–mouse F4/80, CI:A3–1 (Serotec) 1:300 dilution; and rat anti–mouse major basic protein (kind gift from Dr. J. Lee, Mayo Clinic, Scottsdale, AZ). Mouse anti–rat IgG1, IgG2a and IgG2b isotype controls (all from Serotec) were used at appropriate dilutions as controls. Positive-staining cells in the central cornea and the ciliary body were counted. Because rejected corneal allografts demonstrate variable thickness resulting from edema, it was not appropriate to count the number of cells per unit area. Instead, the number of positive cells throughout the full thickness of a 100× field of the central stroma of each section was counted. Cells were counted in three sections per rejected graft. At least five grafts were examined in each group. Sections of the ciliary body were imaged, and their cross-sectional areas were measured using image analysis software (Soft Imaging System GmbH, Munster, Germany). The number of positive-staining cells in each ciliary body section was counted using high magnification and expressed as cells/0.1 mm2. Cells were counted in three sections per eye. At least five eyes were examined in each group.
To study the effects of the sensitization protocol (without challenge) on the recipient cornea, we compared frozen sections from Sens+Chall− eyes with normal eyes and with eyes with suture-induced corneal inflammation. Sections were stained directly with phycoerythrin (PE)-conjugated rat anti–mouse CD11b, M1/70 (BD Biosciences), dilution 1:100, and PE-conjugated rat anti–mouse CD11c, B-ly6 (BD Biosciences), dilution 1:100. Other sections were stained with primary rat anti–mouse LYVE-1, 223322 (R&D Systems Minneapolis, MN), dilution 1:400, and then with secondary Alexa-488–conjugated donkey anti–rat antibody (Invitrogen, Carlsbad, CA). Four eyes per group were examined.